Debt Financing

SciSparc sells $3,000,000 discounted convertible note to repeat financier L.I.A. Pure Capital

SPRC

SciSparc took $2,550,000 for the note, which converts at up to 15% below recent prices with a $0.11592 floor and came with a warrant for 11,457,269 shares. The agreement allows up to $10,000,000 of notes.

Investor Chat

Scorecard

SPRCDebt
Deal Terms: 5/10, Fair termsHow favorable this deal is for the company and existing shareholders, compared with similar financings. · Terms are estimated from available structured facts. Unobserved components use the median prior; transaction linkage is incomplete. · As of 2026-11-05
Fair terms
Investor Impact: 8.2/10, Very highHow important this specific story was to investors when we published it, whether the news was good or bad. · High evidence · As of 2026-11-05
Very highHigh evidence
Company Deal Record: 5/10, Mixed recordHow favorable the company’s past financings have been, with more weight on recent deals. · As of 2026-11-05
Mixed record
Investment Attractiveness: 5/10, MixedThe company’s relative investment appeal, based on financial strength, valuation and execution. · Relative financial and execution position; not a forecast of stock returns. · As of 2026-11-05
Mixed

Debt: loan financing

By the aibio.space news desk

A DNA double helix model lit from behind
A DNA double helix model lit from behind. CC0, via rawpixel. The picture shows the field, not the companies named.

SciSparc Ltd. (Nasdaq: SPRC) sold a $3,000,000 convertible promissory note to L.I.A. Pure Capital Ltd. on November 3, 2026 and was paid $2,550,000 for it. Pure Capital is the same holder that agreed three weeks earlier to convert an older SciSparc note into stock. Oz Adler, Chief Executive Officer and Chief Financial Officer, signed the report and the agreements. Shareholders should look hard at the cost. The note converts at a price that falls with the stock, it came with a warrant for up to 11,457,269 ordinary shares, and the agreement lets SciSparc sell up to $10,000,000 of notes on the same terms. In its latest half-year report the company said its cash could not fund planned operations for a year and that there is substantial doubt about its ability to continue as a going concern. Form 6-K, November 3

The terms

The report itself calls the buyer only "an institutional investor." The exhibit list and signature pages name L.I.A. Pure Capital Ltd., signed by its Chief Executive Officer, Kfir Zilberman. Every note under the agreement is sold at 85% of principal. It pays 4% a year, rising to 14% after an Event of Default. Repayment comes in ten equal monthly installments starting the first day of the month after the eighteenth month. For this note that start date is May 3, 2028. Convertible note

From January 1, 2027, SciSparc may ask Pure Capital to buy further notes of up to $3,000,000 each, one request per three-month period. It can ask sooner if daily trading volume reaches 100% of the shares outstanding. That leaves $7,000,000 unused. The company is not obliged to use it, and there are no minimum use penalties. Form 6-K

Where the dilution sits

Pure Capital can convert at any time. The price is the lower of $0.5237 or 85% of the lowest daily volume weighted average price in the 20 trading days before conversion, with a floor of $0.11592. At that floor the $3,000,000 of principal alone would convert into about 25.9 million shares. A 4.99% ownership cap limits how much Pure Capital can hold at any one time, not how much it can convert and sell over time. The note also bars issuing shares above the limit Nasdaq rules allow without shareholder approval. Convertible note

The warrant adds a second layer. It covers 200% of the shares issuable on conversion, came for no extra payment, is exercisable at $0.5237 and runs to November 2, 2029. If SciSparc sells shares below the exercise price, the price resets to the higher of that new price and $0.11592. Subject to certain exceptions, the warrant is not adjusted for share splits or reverse splits. The report also says exercising the warrant is Pure Capital's sole recourse if SciSparc fails to pay principal and interest, and it does not explain how that clause would work in practice. Form 6-K

Same holder, lower prices

On October 15, SciSparc offered Pure Capital the chance to convert a note issued on February 12, 2026, with $2,023,039.21 of principal and interest, at $1.50 per share. No cash changed hands. Form 6-K, October 15 The same day the company issued a press release titled "SciSparc Announces Transformation into Agentic AI-Powered Technologies, Including Cybersecurity and Finance Technologies." Form 6-K, October 15 On October 26, Pure Capital agreed to exercise warrants for 405,728 shares after SciSparc cut the exercise price from $4.929 to $1.0, for expected gross proceeds of about $405,728. Form 6-K, October 26

The new note's fixed conversion price of $0.5237 is about 35% of the $1.50 offered on October 15. In our reading, each new round of Pure Capital money has been priced well below the one before it.

The cash position

SciSparc had $4.458 million of cash, including short-term restricted deposits and short-term deposits, at June 30, 2026. Operations used $3,561 thousand in the first half, and the net loss was $6,051 thousand. Revenue was $284 thousand, mostly from the hemp-products eCommerce business. The company said these factors raise substantial doubt about its ability to continue as a going concern. Half-year MD&A

What the filings leave out

The filings name no placement agent, underwriter or financial advisor and give no net proceeds after fees. The note sends copies of notices to the company to Meitar Law Offices (Dr. Shachar Hadar, Adv.), but it does not describe the firm's role. The discount is in the price. SciSparc received $2,550,000 and owes $3,000,000 plus interest, and it handed over a warrant on top. The money is for working capital and general corporate purposes. SciSparc must file a registration statement for resale of the conversion and warrant shares. Its risk factors sit in the Form 20-F for 2025, filed April 29, 2026 and amended August 19, 2026. Form 6-K

The next document to watch is that resale registration statement, which will show how many shares SciSparc registers. Any draw after January 1, 2027 would bring another note and another warrant.

Investor Chat

Loading posts…

Settings

Text size
Motion

Stops the moving share lists on the front page.

Your choices are saved in this browser only.

Free membership

Get aibio.space by email, free

Get updates from aibio.space by email. Sign up with your email address to receive updates and offers. Unsubscribe in one click.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address.